This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
protein
product name :
Biotinylated Human BTN1A1 / Butyrophilin Protein, His,Avitag™
catalog :
BT1-H82E6
quantity :
200 ug, 25 ug
price :
1380 USD, 350 USD
product information
company name :
ACROBiosystems
product type :
Protein
catalog :
BT1-H82E6
product name :
Biotinylated Human BTN1A1 / Butyrophilin Protein, His,Avitag™
quantity :
200 ug, 25 ug
price :
1380 USD, 350 USD
quantity & price :
$350/25ug,$1380/200ug
target :
BTN1A1
host species :
Human
By Tag :
His Tag & Avi Tag
Research :
For Research Use Only
Source :
Biotinylated Human BTN1A1, His,Avitag (BT1-H82E6) is expressed from human 293 cells (HEK293). It contains AA Ala 27 - Arg 242 (Accession # Q13410-1).
Endotoxin :
Less than 1.0 EU per μg by the LAL method.
Purity :
>90% as determined by SDS-PAGE.
SDS-PAGE Remark(R&NR) :
Biotinylated Human BTN1A1, His,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.
Formulation :
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation.
Reconstitution :
Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage :
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● -20°C to -70°C for 12 months in lyophilized state;
● -70℃ for 3 months under sterile conditions after reconstitution.
Background :
Butyrophilin subfamily 1 member A1 (BTN1A1) is also known as BTN, which is a member of the immunoglobulin superfamily and the major protein associated with fat droplets in the milk. BTN1A1 may have a cell surface receptor function. The human butyrophilin gene is localized in the major histocompatibility complex (MHC) class I region of 6p and may have arisen relatively recently in evolution by the shuffling of exons between 2 ancestral gene families. Furthermore, BTN1A1 regulates the amount of lipids and size of droplets expressed in milk and inhibits the proliferation of CD4 and CD8 T-cells activated by anti-CD3 antibodies, T-cell metabolism and IL2 and IFNG secretion.
References :
(1) Taylor M.R., et al., 1996, Biochim. Biophys. Acta 1306:1-4.
(2) Mather IH., et al., 1993, J. Dairy Sci. 76 (12): 3832–50.
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments